Nicola Greenlaw

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Paul R. Kalra, John G.F. Cleland, Mark C. Petrie et al. · The Lancet · 2022 · 344 citations · Full text

Heart Failure, Intravenous Ferric Derisomaltose, Iron Metabolism +3

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

John R. Petrie, Nish Chaturvedi, Ian Ford et al. · The Lancet Diabetes & Endocrinology · 2017 · 337 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +7

Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial

Anthony D. Ormerod, Kim S Thomas, Fiona E. Craig et al. · BMJ · 2015 · 249 citations · Full text

Intravenous Ferric Carboxymaltose in Iron-Deficient Chronic Heart Failure Patients with and Without Anaemia: a Subanalysis of the FAIR-HF Trial

Gerasimos Filippatos, Dimitrios Farmakis, Josep Comín Colet et al. · European Journal of Heart Failure · 2013 · 156 citations · Full text

Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease

Philippe Gabríel Steg, Nicola Greenlaw, Michał Tendera et al. · JAMA Internal Medicine · 2014 · 143 citations